
Opinion|Videos|April 4, 2025
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
- What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
- How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
4
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
5